Mankind Pharma News and Updates

Name: Latest research reports of Mankind Pharma Ltd. authored by Swastika and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 5
Author: Swastika

Keep track of all breaking news on Mankind Pharma from all sources in a single place.

Load latest

Mankind Pharma Ltd.

31 May 2023

2205.60

-0.49%

to see Rapid results content

Mankind Pharma Ltd.

26 Apr 2023

2205.60

-0.49%

IPO Note

IPO Subscribe: Mankind Pharma Ltd.

Swastika

Incorporated in 1991, Mankind Pharma Limited is a pharmaceutical company which is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Geojit BNP Paribas upgraded Mankind Pharma Ltd. to Buy with a price target of 2600.0 on 26 Nov, 2025.

Mankind Pharma Ltd.

26 Apr 2023

2205.60

-0.49%

IPO DETAILS

IPO Subscribe: Mankind Pharma Ltd.

Marwadi Financial Services

Considering the TTM (Dec-22) /FY23 Annualized EPS of Rs 29.61/33.16 on a post-issue basis, the company is going to list at a P/E of 36.47/32.57x with a market cap of Rs. 4,32,636 mn. whereas its peers namely Sun Pharmaceuticals, Cipla, Alkem Lab and Torrent Pharmaceutical are trading at a P/E of 29.43x, 27.45x, 39.24x, 43.65x.

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

25 Apr 2023

2205.60

-0.49%

MANKIND PHARMA LTD.

IPO Note: Mankind Pharma Ltd.

Ventura

IPO NOTE

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

24 Apr 2023

2205.60

-0.49%

MANKIND PHARMA

IPO Subscribe: Mankind Pharma Ltd.

Hem Securities

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

24 Apr 2023

2205.60

-0.49%

Calibrated approach in domestic branded formulations.

IPO Subscribe: Mankind Pharma Ltd.

ICICI Direct

Mankind is the fourth largest player in the domestic market with a presence across therapy areas like anti-infectives, cardiac, gastro, respiratory and also in consumer healthcare segments like condoms, acne preparations, emergency contraceptives, pregnancy tests among others.

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

24 Apr 2023

2205.60

-0.49%

IPO Note

IPO Subscribe: Mankind Pharma Ltd.

Canara Bank Securities

Mankind Pharma Ltd. (“Mankind”) is India’s 4th largest pharmaceutical company in terms of Domestic sales and 3 rd largest in terms of sales volume for MAT (Moving An nual Total) December 2022 engaged in diverse range of pharmaceutical formulation across acute and chronic therapeutic areas.

Geojit BNP Paribas upgraded Mankind Pharma Ltd. to Buy with a price target of 2600.0 on 26 Nov, 2025.

Mankind Pharma Ltd.

24 Apr 2023

2205.60

-0.49%

Mankind Pharma Limited

IPO Subscribe: Mankind Pharma Ltd.

Asit C Mehta Investment Interrmediates

Mankind benefits from the industry experience and business acumen of their individual Promoters and is driven by the 3 core values of quality, affordability and accessibility. Their professional and experienced management team has been critical in building their brands, growing their operations, and maintaining capital efficiency despite their emphasis on affordable product offerings.

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

24 Apr 2023

2205.60

-0.49%

Strong domestic market position through a diversified product portfolio

IPO Subscribe: Mankind Pharma Ltd.

Aditya Birla Money Limited

MPL focuses primarily on the domestic market (98% of sales) with market share increasing from 4.1% to 4.3% over FY20 - MAT Dec’22 with sales growing at 12% CAGR v/s IPM (Indian Pharmaceutical Market) growth of around 10% for the same period.